$0.0588
-0.00800-11.98%
At close: -
$0.0550
-0.00380-6.46%
After Hours: Mar 17, 9:29 AM EDT
Comments
Loading...
BetterLife Pharma Analyst Ratings and Price Targets | OTC:BETRF | Benzinga
BetterLife Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for BetterLife Pharma Corp from these most-recent analyst ratings.
Analyst Ratings for BetterLife Pharma
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for BetterLife Pharma (BETRF) stock?
There is no price target for BetterLife Pharma
What is the most recent analyst rating for BetterLife Pharma (BETRF)?
There is no analyst for BetterLife Pharma
When was the last upgrade for BetterLife Pharma (BETRF)?
There is no last upgrade for BetterLife Pharma
When was the last downgrade for BetterLife Pharma (BETRF)?
There is no last downgrade for BetterLife Pharma.
When is the next analyst rating going to be posted or updated for BetterLife Pharma (BETRF)?
There is no next analyst rating for BetterLife Pharma.
Is the Analyst Rating BetterLife Pharma (BETRF) correct?
There is no next analyst rating for BetterLife Pharma.
Browse analyst ratings and price targets on all stocks.